Antifibrotic Activity of Bevacizumab on Human Tenon's Fibroblasts In Vitro
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
PURPOSE: To evaluate the effect of the anti-VEGF-A monoclonal antibody bevacizumab on primary human Tenon's capsule fibroblasts (HTFs) in an in vitro model of wound healing. METHODS: Fibroblasts were cultured in RPMI media, and bevacizumab was administered at a concentration ranging from 0.25 to 12.5 mg/mL. Fibroblast viability and cell death were assessed using the MTT colorimetric assay, lactate dehydrogenase assay, BrdU assay, and live/dead assay. Fibroblast contractility was assessed in floating collagen gels. Morphologic changes were assessed by transmission electron microscopy. Antifibrosis activities were compared with 5-fluorouracil. RESULTS: Bevacizumab induced a significant dose-related reduction of HTF cell number at 12.5 mg/mL at 72 hours (P < 0.05). Under serum-free conditions, bevacizumab induced significant fibroblast cell death at concentrations greater than 7.5 mg/mL (P < 0.05). Bevacizumab caused a moderate inhibition of fibroblast gel contraction from baseline (P < 0.05). Scanning electron microscopy revealed marked vacuolization in bevacizumab-treated fibroblasts. CONCLUSIONS: Bevacizumab disrupted fibroblast proliferation, inhibited collagen gel contraction ability, and induced fibroblast cell death at concentrations greater than 7.5 mg/mL in serum-free conditions. These results demonstrated that bevacizumab inhibited a number of fibrosis activities in culture. These activities may underpin the antifibrosis effect proposed in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bevacizumab is reported to have antifibrotic activity that reduces scar formation in glaucoma filtration surgery.29–31”
From Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials (2014) · cites this paper as [29]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“, South San Francisco, CA) is a full-length humanized monoclonal antibody directed against all isoforms of VEGF-A (VEGF-121, -145, -165, -183, -189, and -209) and is approved by the US Food and Drug Administration for the treatment of metastatic colorectal and metastatic breast cancer.(17,18) It binds and neutralizes…”
BackgroundAngiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“It binds and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments.(20) Wound healing complications, including early delayed wound closure or dehiscence in anastomosis (after colorectal surgery), have been reported after the administration of intravenous bevacizumab.”
BackgroundClinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517 · cited 1×
“As a result multiple antiangiogenic agents, targeting VEGF-A or its receptor VEGFR2, have been developed to specifically target and treat VEGFA– driven ocular pathology.(14) Anti-VEGF monoclonal antibodies have been developed to treat solid tumors(16) –18 and now also form part of the clinical management of ocular neo…”
BackgroundIntravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,133
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
Shibuya, M., & Claesson-Welsh, L. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.012 · Cited by 1,062
Cursiefen, C., Chen, L., Borges, L. P., Jackson, D. G., Cao, J., Radziejewski, C. H., D'Amore, P. A., Dana, M. R., Wiegand, S. J., & Streilein, J. W. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420465 · Cited by 1,059
Nissen, N., Polverini, P. J., Koch, A. E., Volin, M. V., Gamelli, R. L., & DiPietro, L. A. (1998) · Europe PMC (PubMed Central) · Cited by 965
Cited by
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Daniel, E., Toth, C. A., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Fine, S. L., Huang, J., Ying, G.-S., Hagstrom, S. A., Winter, K., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.019 · Cited by 335
Conjunctival fibrosis following filtering glaucoma surgery
Schlunck, G., Meyer-ter-Vehn, T., Klink, T., & Grehn, F. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2015.03.021 · Cited by 175
“, 2011), which was inhibited by an anti-VEGF antibody (Li et al., 2009; O'Neill et al., 2010).”
BackgroundWound Modulation After Filtration Surgery
Seibold, L. K., Sherwood, M. B., & Kahook, M. Y. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.008 · Cited by 167
Schulze‐Tanzil, G., Al‐Sadi, O., Wiegand, E., Ertel, W., Busch, C., Kohl, B., & Pufe, T. (2011) · Scandinavian Journal of Medicine & Science in Sports · doi:10.1111/j.1600-0838.2010.01265.x · Cited by 158
“The knowledge should be used to further develop immunoregulatory strategies to improve tendon healing such as the use of anti-inflammatory cytokines (Courneya et al., 2010) or anti-angiogenesis agents such as bevacizumab (avastin) (Mizote et al., 2010; O’Neill et al., 2010).”
BackgroundModulation of Fibroblasts in Conjunctival Wound Healing
Zada, M., Pattamatta, U., & White, A. J. R. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.08.028 · Cited by 114
The role of matricellular proteins in glaucoma
Wallace, D. M., Murphy-Ullrich, J. E., Downs, J. C., & O'Brien, C. J. (2014) · Matrix Biology · doi:10.1016/j.matbio.2014.03.007 · Cited by 97
“The anti-fibrotic and anti-proliferative effects of Bevacizumab (O'Neill et al., 2010) and Paclitaxel (Choritz et al.”
VEGF Induces TGF-β1 Expression and Myofibroblast Transformation after Glaucoma Surgery
Park, H. L., Kim, J., & Park, C. K. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.02.009 · Cited by 82
“AntiVEGF agents, such as bevacizumab, have shown antifibrotic effects via the inhibition of fibroblast proliferation and the induction of fibroblast cell death in vitro.(30) In addition, our results suggest that VEGF inhibition may play a role in the reduction of scar formation by decreasing myofibroblast”
Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study
Vandewalle, E., Pinto, L. A., Bergen, T. V., Spielberg, L. H., Fieuws, S., Moons, L., Spileers, W., Zeyen, T. G., & Stalmans, I. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303966 · Cited by 74
Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review
Kim, M., Lee, C., Payne, R. M., Yue, B. Y. J. T., Chang, J.-H., & Ying, H. (2015) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2015.04.003 · Cited by 69
Recent Advances in the Management of Neovascular Glaucoma
SooHoo, J. R., Seibold, L. K., & Kahook, M. Y. (2013) · Seminars in Ophthalmology · doi:10.3109/08820538.2012.730103 · Cited by 60
Zadorozhna, M., Gioia, S. D., Conese, M., & Mangieri, D. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05290-0 · Cited by 60
“It also shows a strong anti-fibrotic effect in human Tenon’s fibrosis [83].”
BackgroundLevel of Vascular Endothelial Growth Factor in Tenon Tissue and Results of Glaucoma Surgery
Park, H.-Y. L., Kim, J., Ahn, M. D., & Park, C. K. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.2799 · Cited by 57
The effect of intravitreal bevacizumab injection as the initial treatment for Coats’ disease
Zheng, X., & Jiang, Y. (2013) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-013-2409-1 · Cited by 52
“[27] reported that bevacizumab could disrupt fibroblast proliferation, inhibit collagen gel contraction ability, and induce fibroblast cell death in culture.”
BackgroundAnti–Vascular Endothelial Growth Factor Therapy in Glaucoma Filtration Surgery
Mathew, R. G., & Barton, K. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.03.013 · Cited by 43
Bleb vascularity following post‐trabeculectomy subconjunctival bevacizumab: a pilot study
Chua, B., Nguyen, D. Q., Qin, Q., Ruddle, J. B., Wells, A. P., Niyadurupola, N., Gupta, V., Wong, T. T. L., Coote, M., & Crowston, J. G. (2012) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2012.02798.x · Cited by 41
Self-citationGrover, D. S., Kornmann, H. L., & Fellman, R. L. (2020) · Journal of Glaucoma · doi:10.1097/ijg.0000000000001438 · Cited by 40
Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery
Cheng, J.-W., Cheng, S., Wei, R.-L., & Lu, G. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009782.pub2 · Cited by 40
Soluble VEGF receptor 1 (sFLT1) induces non-apoptotic death in ovarian and colorectal cancer cells
Miyake, T., Kumasawa, K., Sato, N., Takiuchi, T., Nakamura, H., & Kimura, T. (2016) · Scientific Reports · doi:10.1038/srep24853 · Cited by 37
Freiberg, F. J., Matlach, J., Grehn, F. J., Klink, & Karl, K. (2013) · Clinical ophthalmology · doi:10.2147/opth.s41750 · Cited by 34
Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab
Park, S. C., Su, D., & Tello, C. A. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.721772 · Cited by 33
“Two in vitro studies confirmed the direct effect of anti-VEGF on human tenon fibroblast proliferation [46,47].”
BackgroundFALCO, E. D., Scafetta, G., Napoletano, C., Puca, R., Vingolo, E. M., Ragona, G., Iorio, O., & Frati, G. (2012) · Cell and Tissue Banking · doi:10.1007/s10561-012-9325-1 · Cited by 32
Liu, X., Du, L., & Li, N. (2016) · Medicine · doi:10.1097/md.0000000000003223 · Cited by 32
Emami, M. J., Jaberi, F. M., Azarpira, N., Vosoughi, A. R., & Tanideh, N. (2012) · Orthopaedics & Traumatology Surgery & Research · doi:10.1016/j.otsr.2012.05.020 · Cited by 30
Vahedian, Z., Mafi, M., Fakhraie, G., Zarei, R., Eslami, Y., Ghadimi, H., & Mohebbi, M. (2017) · Journal of Glaucoma · doi:10.1097/ijg.0000000000000741 · Cited by 27
Bagheri, A., Soheili, Z., Ahmadieh, H., Samiei, S., Sheibani, N., Astaneh, S. D., Kanavi, M. R., & Mohammadian, A. (2015) · PubMed Central · Cited by 24
Fakhraie, G., Ghadimi, H., Eslami, Y., Zarei, R., Mohammadi, M., Vahedian, Z., Mafi, M., & Moghimi, S. (2014) · Journal of Glaucoma · doi:10.1097/ijg.0000000000000202 · Cited by 24
O’Connor, J., Ang, G. S., Gaskin, J. C. F., Nguyen, D. Q., & Crowston, J. G. (2014) · JOURNAL OF CURRENT GLAUCOMA PRACTICE · doi:10.5005/jp-journals-10008-1160 · Cited by 23
Self-citationDeep Sclerectomy With Bevacizumab and Mitomycin C: A Comparative Study
Anand, N., & Bong, C. X. (2013) · Journal of Glaucoma · doi:10.1097/ijg.0b013e3182883c0c · Cited by 21
Effect of Bevacizumab on Human Tenon's Fibroblasts Cultured from Primary and Recurrent Pterygium
Park, Y. M., Kim, C. D., & Lee, J. S. (2015) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2015.19.4.357 · Cited by 20
“[20]’s report that bevacizumab inhibits fibroblast proliferation and induces fibroblast cell death in addition to its effect on angiogenesis.”
BackgroundZhang, Y., Zhu, S., Xu, X., & Zuo, L. (2019) · Journal of Ophthalmology · doi:10.1155/2019/7419571 · Cited by 17
“Anti-VEGF adjuncts are preliminarily tested in vitro [34], animal studies [12, 35], and small clinical trials [36–40].”
BackgroundNilforushan, N., Es’haghi, A., Miraftabi, A., Abolfathzadeh, N., & Banifatemi, M. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-317324 · Cited by 16
Rosmarinic Acid Suppresses Subconjunctival Neovascularization in Experimental Glaucoma Surgery
Ferreira, J. D. L. M., Chahud, F., Ramalho, L. N. Z., Módulo, C. M., Vieira, L. C., Reinach, P. S., Rodrigues, M. D. L. V., Silva‐Cunha, A., & Paula, J. S. (2014) · Current Eye Research · doi:10.3109/02713683.2014.980911 · Cited by 14
Zuo, L., Zhang, J., & Xu, X. (2018) · Journal of Ophthalmology · doi:10.1155/2018/8965709 · Cited by 13
“In vitro studies have reported the inhibitory eect of BVZ on the proliferation and migration of Tenon’s broblast cells [18, 49].”
Ada, S., Ersan, S., Sifil, A., Ünlü, M., Kolatan, E., Sert, M., Sarıoğlu, S., Yılmaz, O., & Çamsarı, T. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-1116-8 · Cited by 12
“In this study, bevacizumab, through the inhibition of VEGF-A, exerts a potent antifibrotic effect through the inhibition of fibroblast proliferation, induction of fibroblast cell death, and inhibition of cell-mediated collagen gel contraction [27].”
BackgroundMa, J., Zhang, Q., Moe, M. C., & Zhu, T. (2011) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2011.02618.x · Cited by 11
“Furthermore, it has been shown that the anti-VEGF-A monoclonal antibody bevacizumab can inhibit collagen gel contraction ability and fibrosis activities in fibroblast culture, underpinning the proposed antifibrotic effect of VEGF in vivo.(18) As anti-VEGF therapy now is widely used in the clinic, a correlation between…”
BackgroundShah, M. H., Chan, E. C., Bergen, N. J. V., Pandav, S. S., Ng, S. W., Crowston, J. G., & Peshavariya, H. (2020) · Antioxidants · doi:10.3390/antiox9111126 · Cited by 11
“As previously described, HTFs were derived from explanted subconjunctival Tenon’s capsule collected during GFS performed in patients [16].”
MethodSelf-citationBhasin, P., Gujar, P., & Bhasin, P. (2012) · Cornea · doi:10.1097/ico.0b013e318245c044 · Cited by 11
Noh, S. M. M., Kadir, S. H. S. A., Crowston, J. G., Subrayan, V., & Vasudevan, S. K. (2015) · PubMed Central · Cited by 10
Self-citationEffects of ranibizumab on the extracellular matrix production by human Tenon's fibroblast
Noh, S. M. M., Kadir, S. H. S. A., Bannur, Z., Froemming, G. R. A., Hasani, N. A. H., Nawawi, H. M., Crowston, J. G., & Vasudevan, S. K. (2014) · Experimental Eye Research · doi:10.1016/j.exer.2014.08.005 · Cited by 10
Self-citationFischer, C., Mans, V., Horn, M., Naxer, S., Klettner, A., & van Oterendorp, C. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19938 · Cited by 9
Nikhalashree, S., George, R. J., Balekudaru, S., Vijaya, L., Sulochana, K. N., & Coral, K. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109199 · Cited by 9
Intracameral bevacizumab role in trabeculectomy: A 1-year prospective randomized controlled study
Rabina, G., Barequet, D., Mimouni, M., Kurtz, S., Shemesh, G., Rosenblatt, A., & Rosenfeld, E. (2019) · European Journal of Ophthalmology · doi:10.1177/1120672119874682 · Cited by 8
Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery
Cheng, J.-W., Cheng, S., Wei, R.-L., & Lu, G. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009782 · Cited by 8
Franco, L., Rassi, B. T., de Ávila, M. P., & Magacho, L. (2015) · European Journal of Ophthalmology · doi:10.5301/ejo.5000688 · Cited by 6
“Furthermore, it was demonstrated that bevacizumab leads to a dose-dependent suppression of cell proliferation (18).”
BackgroundSubconjunctival Bevacizumab Injection in Glaucoma Filtering Surgery: A Case Control Series
Wang, J., & Harasymowycz, P. J. (2013) · ISRN Ophthalmology · doi:10.1155/2013/384134 · Cited by 6
“In vitro cell cultures have also demonstrated that the application of bevacizumab inhibited Tenon fibroblasts proliferation, reduced collagen deposition, and induced apoptosis of fibroblasts [6, 13].”
BackgroundVakilian, S., Al‐Hashmi, S., Al‐kindi, J., Al‐Fahdi, F., Al‐Wahaibi, N., Shalaby, A., Al‐Riyami, H., Al‐Harrasi, A., & Jamshidi‐adegani, F. (2024) · Macromolecular Bioscience · doi:10.1002/mabi.202300530 · Cited by 5
VEGF inhibitors in glaucoma surgery
Mamikonyan, V. R., Petrov, S. Y., & Максимовна, С. Д. (2016) · Ophthalmology Reports · doi:10.17816/ov9147-55 · Cited by 5
Trabekulektomie mit Ologen®-Implantat und Bevacizumab
Glandorf, K., Lommatzsch, C., Heinz, C., & Koch, J. M. (2019) · Der Ophthalmologe · doi:10.1007/s00347-019-00972-y · Cited by 5
Pavel, M.-C., Casanova, R., Estalella, L., Memba, R., Llàcer-Millán, E., Julià, E., Merino, S., Geoghegan, J., & Jorba, R. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.12.017 · Cited by 5
Xiong, B., Bai, Y., Liu, J., Li, T., Wang, Y., & Zhou, C. (2024) · Portal hypertension & cirrhosis · doi:10.1002/poh2.75 · Cited by 4
Liu, W., & Liu, B. (2023) · International Wound Journal · doi:10.1111/iwj.14517 · Cited by 4
“12 The development of scar tissue is the main reason for the failure of the blister following trabeculectomy, which influences the long-term success.”
BackgroundRetractedKim, J. L., Lee, H. S., Lee, Y., Kang, M. S., Lee, S. J., & Yang, J. W. (2017) · Current Eye Research · doi:10.1080/02713683.2016.1257727 · Cited by 4
“Anti-VEGF agents have exhibited antifibrotic effects through the inhibition of fibroblast proliferation and the induction of fibroblast cell death in vitro.(37) Several studies have reported that the inhibition of VEGF results in reductions in the wound healing response in the GFS bleb and improves the outcomes of GFS.”
BackgroundBevacizumab Promotes T-Cell–Mediated Collagen Deposition in the Mouse Model of Conjunctival Scarring
Seet, L., Toh, L. Z., Chu, S. W. L., Finger, S. N., Ginhoux, F., Hong, W., & Wong, T. T. L. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22694 · Cited by 4
Self-citationLanzagorta-Aresti, A., Pérez‐López, M., Davó-Cabrera, J. M., & Palacios-Pozo, E. (2018) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2018-000165 · Cited by 3
Yoon, S. Y., Kim, E., Han, G. S., Suh, L. H., Jung, H. S., Tchah, H., & Kim, J. Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219194 · Cited by 3
Yoon, S. Y., Kim, E., Han, G. S., Suh, L. H., Jung, H. S., Tchah, H., & Kim, J. Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226662 · Cited by 3
Post-trabeculectomy topical bevacizumab preventing bleb failure: a preliminary study
Bhasker, S. K., Saxena, S., & Singh, K. (2012) · Journal of ocular biology, diseases, and informatics · doi:10.1007/s12177-013-9108-3 · Cited by 2
Impact of Bevacizumab on Liver Damage After Massive Hepatectomy in Rats
Mori, H., Saito, Y., Iwahashi, S., Ikemoto, T., Imura, S., Morine, Y., & Shimada, M. (2019) · In Vivo · doi:10.21873/invivo.11626 · Cited by 2
Scheidt, M. D., Ellman, M. B., & Bhatia, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-71310-8.00035-9 · Cited by 2
Kim, J. J., & Shin, J. P. (2013) · Journal of the Korean Ophthalmological Society · doi:10.3341/jkos.2013.54.5.757 · Cited by 2
Short-Term Results of Sutureless Scleral Tunnel Trabeculectomy Using Adjunctive Topical Bevacizumab.
Arish, M., Bagherzadeh, O., Ahmadi, S. S., Sadeghi, J., & Hassanzadeh, S. (2018) · Medical Hypothesis Discovery & Innovation in Ophthalmology · Cited by 2
Said, A. M. A., Zaki, R. G. E., Mohamed, T. H., & Salman, M. I. (2016) · International Journal of Ophthalmology · doi:10.18240/ijo.2016.03.04 · Cited by 1
Höh, H., Holland, U., & Medra, A. (2019) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-0972-1427 · Cited by 1
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
Kitnarong, N., Kittipiriyakul, J., & Jiravarnsirikul, A. (2022) · Siriraj Medical Journal/San Sirirat · doi:10.33192/smj.2022.4 · Cited by 1
Filtrierende Glaukomchirurgie – Verfahren mit Bildung eines Filterkissens
Bahlmann, D., & van Oterendorp, C. (2024) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-2305-5053 · Cited by 1
The Effect of Bevacizumab on Human Tenon Fibroblasts in Ocular Wound Healing
Bergen, T. V., & Stalmans, I. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6116 · Cited by 1
Arthrofibrosis Prevention by Antibody against Vascular Endothelial Growth Factor
Emami, M. J., Jaberi, F. M., Azarpira, N., Vosoughi, A. R., & Tanideh, D. (2013) · Iranian Journal of Orthopaedic Surgery
Ferreira, J. D. L. M. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2015.tde-03082015-143606
Late Failure of Filtering Bleb
Stamper, R. L., & Chen, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-7020-5193-7.00085-6
Sitoresmi, S. A., Nurwasis, N., Komaratih, E., & Heriyawatih (2020) · International Journal of Psychosocial Rehabilitation · doi:10.37200/ijpr/v24i2/pr200724
Grover, D. S., Kornmann, H. L., & Fellman, R. L. (2020) · Journal of Glaucoma · doi:10.1097/ijg.0000000000001515
Xiang, X., Luo, L., Chen, Y., Ye, F., Fu, Y., & Tang, M. M. (2020) · Research Square · doi:10.21203/rs.2.14174/v2
Arish, M., Sargazi, M., Dehghani, S., Sahami, M., Dashipour, A., Sarhadi, S., & Rouientan, H. (2023) · International Ophthalmology · doi:10.1007/s10792-023-02833-9
Filtrierende Glaukomchirurgie – Verfahren mit Bildung eines Filterkissens
Bahlmann, D., & van Oterendorp, C. (2024) · Augenheilkunde up2date · doi:10.1055/a-2119-0513
Tacrolimus Inhibits Human Tenon’s Fibroblast Migration, Proliferation, and Transdifferentiation
Hur, W., Park, J., Lee, J.-H., Chung, H.-S., Shin, J. A., Lee, H., Tchah, H., & Kim, J. Y. (2025) · Biomedicines · doi:10.3390/biomedicines13122956
“Moreover, it was reported in 2010 that bevacizumab had an antifibrotic effect on human Tenon’s fibroblast (HTF) cells in vitro [14].”
Ansari, A. S., Ramji, S., Tan, J. C. K., Ansari, D. M., Jarrar, Z. A., Hamid, S., & Gazzard, G. (2026) · AJO International · doi:10.1016/j.ajoint.2026.100254
Pantola, P., Gupta, S., Kaur, G., Kumar, P., Pathania, M., & Taank, P. (2026) · Romanian Journal of Ophthalmology · doi:10.22336/rjo.2026.54
Metadata
- Authors
- O'Neill, E. C., Qin, Q., Van Bergen, N. J., Connell, P. P., Vasudevan, S., Coote, M. A., Trounce, I. A., Wong, T. T. L., & Crowston, J. G.
- Affiliations
- From the Centre for Eye Research Australia, the Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia;
- The Royal Victorian Eye & Ear Hospital (AU)
- Singapore National Eye Center (SG)
- Corresponding author
- Qin, Queena
- Connell, Paul P.
- Vasudevan, Sushil
- Coote, Michael A.
- Trounce, Ian A.
- Wong, Tina T. L.
- Crowston, Jonathan G.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2010-12-01
- Volume
- 51
- Issue
- 12
- Pages
- 6524
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2017909699
- Cited by
- 73
- References
- 44
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 5 · 2019: 6 · 2018: 4 · 2017: 3 · 2016: 6 · 2015: 8 · 2014: 6 · 2013: 10 · 2012: 9
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Corneal Surgery and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Surgery › Wound Healing and Treatments
- Keywords
- bevacizumab, Tenon's capsule fibroblasts, antifibrotic activity, VEGF-A, fibroblast proliferation, collagen gel contraction, wound healing, vacuolization, 5-fluorouracil, ocular fibrosis
- MeSH terms
- Bevacizumab, Antibodies, Monoclonal, Cell Count, Cells, Cultured, DNA, Dose-Response Relationship, Drug, Fibroblasts, Humans, L-Lactate Dehydrogenase, Microscopy, Electron, Microscopy, Fluorescence, Wound Healing, Apoptosis, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Cell Proliferation, Tenon Capsule, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.